Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer

2013 ◽  
Vol 27 (1) ◽  
pp. 42-49 ◽  
Author(s):  
M. Makazu ◽  
K. Kato ◽  
H. Takisawa ◽  
S. Yoshinaga ◽  
I. Oda ◽  
...  
Keyword(s):  
Endoscopic Mucosal Resection ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Salvage Treatment ◽  
Local Failure ◽  
Esophageal Squamous Cell Cancer ◽  
Definitive Chemoradiotherapy ◽  
Mucosal Resection ◽  
Stage Ib

Endoscopic mucosal resection of early esophageal squamous cell cancer using the Duette mucosectomy kit

Endoscopy ◽  
2006 ◽  
Vol 38 (10) ◽  
pp. 1029-1031 ◽  
Author(s):  
S. Seewald ◽  
T. Ang ◽  
S. Omar ◽  
S. Groth ◽  
F. Dy ◽  
...  
Keyword(s):  
Endoscopic Mucosal Resection ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
Mucosal Resection

Endoscopic resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage II or III esophageal squamous cell cancer.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 109-109
Author(s):  
Makomo Makazu ◽  
Ken Kato ◽  
Hajime Takisawa ◽  
Shigetaka Yoshinaga ◽  
Ichiro Oda ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Survival Rate ◽  
Endoscopic Resection ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Residual Tumor ◽  
Local Failure ◽  
Esophageal Squamous Cell Cancer ◽  
Stage Ii

109 Background: Local failure after definitive chemotherapy and/or radiotherapy for stage II or III esophageal cancer is one of the causes of poor outcome. Endoscopic resection (ER) is an effective treatment for superficial esophageal cancer. However, its curative potential and safety remain unclear for local recurrent or residual tumor. Methods: Two hundred and sixty patients (pts.) who received definitive chemotherapy and/or radiotherapy for stage II or III esophageal squamous cell cancer between January 2000 and July 2007 were retrospectively reviewed. Results: Characteristics of all patients were as follows: median age of 65 (range 35-86); male/female: 226/34; performance status 0/1/2:117/141/2; clinical stage IIA/IIB/III: 64/70/126; regimen of chemoradiotherapy/radiotherapy: 235/15; and radiation dose 50.4/60/>66 Gy: 31/218/10. Of 260pts, 170 (65%) achieved complete response after chemoradiotherapy. Median survival time was 38.5 months and 5-year survival rate was 43.5%. While 81 of them had recurrent disease, 39 had locoregional recurrence without distant metastasis. While 86 of 260 pts (33%) had residual disease after chemoradiotherapy, 68 had only locoregional disease. Of the 107 pts who had only locoregional recurrent or residual tumor, 15 (14%) underwent salvage ER (17 lesions in total). Tumor depth was limited in mucosal layer in 10 lesions and submucosal in 7 lesions. En bloc resection was performed in 9 lesions (52.9%). The vertical margin was free from cancer cells in 15 lesions (88.2%). No major complications, such as hemorrhage requiring blood transfusion and perforation, were experienced. Only one pt experienced minor hemorrhage 16 days after EMR, and was treated by endoscopic treatment. At a median follow-up period of 40.0 months (range, 0.7-94 months) after salvage ER, no recurrence was detected in 9 pts. (60%). Local recurrence was detected in 4 pts. (27%). The clinical courses of the remaining 2 pts were unknown. Three-year survival rate after salvage ER was 58%. Conclusions: Salvage ER is feasible and one of the promising treatments for local recurrent or residual esophageal cancer after chemoradiotherapy or radiotherapy.

Sign in / Sign up

Export Citation Format

Share Document